4d Pharma Share Discussion Threads

[the stigologist] 14/10/2020 07:51

To be presenting THREE Presentations on just one of our Live Biotherapeutics at a Major Cancer Conference is incredible.

The Industry knows the import of what 4D are doing even if the cuck UK investor market is oblivious

10 bags only gets us to HALF Seres' valuation

100 bags is the true potential of this technology platform

[kcowe] 14/10/2020 07:49

That my thinking Inaminute. Bolstering the price , for a raise ?

[realist1950] 14/10/2020 07:44

4d Pharma PLC Presentations on MRx0518 at SITC 2020
14/10/2020 7:00am
RNS Non-Regulatory

TIDMDDDD

4d Pharma PLC

14 October 2020

4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020

Initial immune modulation and safety data from MRx0518 neoadjuvant monotherapy trial in patients awaiting surgical resection of solid tumors

Update on safety and efficacy results of Part A of combination trial of MRx0518 and Keytruda(R) in patients refractory to immune checkpoint inhibitors

Further information on ongoing Part B cohort expansion phase of MRx0518 and Keytruda(R) combination trial

Leeds, UK - October 14, 2020 - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the acceptance of multiple presentations at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting, November 9-14, 2020. The three posters will focus on two of 4D pharma's clinical trials of lead immuno-oncology single strain Live Biotherapeutic MRx0518.

The first poster will describe initial immune modulation and safety data from the MRx0518 neoadjuvant monotherapy trial in patients awaiting surgical resection of solid tumors.

Two further posters will provide details of the MRx0518 and Keytruda(R) (pembrolizumab) combination study in patients who are refractory to immune checkpoint inhibitors. One will provide an additional update on safety and clinical efficacy in patients from the concluded Part A of the study. The second will provide information on the ongoing cohort expansion phase of the trial, Part B.

"4D pharma is building significant amounts of clinical oncology data that demonstrate the potential of single strain Live Biotherapeutics as treatments for a range of solid tumors, including refractory patients with no alternative treatment options. It is critical for us to share this ground-breaking data at events like SITC to continue to push this exciting field forward," said Dr. Alex Stevenson, Chief Scientific Officer of 4D pharma. "For the first time, we will be reporting initial immune modulation and safety data from 4D pharma's study of the MRx0518 as a neoadjuvant monotherapy. This data could be particularly important in developing our understanding of the mechanism of action of MRx0518 in the clinical setting, a key component of maximising its potential as a novel immuno-oncology therapeutic. In addition, having reported initial proof-of-concept for the MRx0518 and Keytruda combination study earlier this year, SITC provides the ideal platform to provide an update on progress with this study."

SITC 2020 Poster Presentation Details:

Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumors

Abstract Number: 805

Presented: 11-14 Nov Virtual Poster Hall

Q&A Session: 11 Nov 5:15-5:45pm EST & 13 Nov 4:40-5:10pm EST

A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors

Abstract Number: 710

Presented: 11-14 Nov Virtual Poster Hall

Q&A Session: 12 Nov 4:50-5:20pm EST & 14 Nov 1-1:30pm EST

Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Abstract Number: 609

Presented: 11-14 Nov Virtual Poster Hall

Q&A Session: 11 Nov 5:15-5:45pm EST & 13 Nov 4:40-5:10pm EST

[divmad] 14/10/2020 07:35

No need, someone else did that for me already. The key reason I am here is for Mx0518. Today's RNS is what DDDD is really about and what will really as significant value for shareholders. The rest is PR basically.

[inaminute] 14/10/2020 07:19

That RNS looks like a good way of bolstering the share price with the promise of jam tomorrow. Would not be presenting what is apparently 'critical' without foundation.

[showmethemoneyhoney01] 14/10/2020 07:18

Divmad, are you going to mention Covid19 delays too?

[conradj1] 14/10/2020 07:17

no one listens to you christh with the way you have trashed the BOO thread with your ramptastic rubbish

[christh] 14/10/2020 07:16

Lets hope the IBS treatment is correct and offered to the public as there so many people suffering from it.

[beaujolly] 14/10/2020 07:09

divmad
£10 million at the end of June plus £7 million raised since.

[showmethemoneyhoney01] 14/10/2020 07:08

"For the first time, we will be reporting initial immune modulation and safety data from 4D pharma's study of the MRx0518 as a neoadjuvant monotherapy. This data could be particularly important in developing our understanding of the mechanism of action of MRx0518 in the clinical setting, a key component of maximising its potential as a novel immuno-oncology therapeutic. In addition, having reported initial proof-of-concept for the MRx0518 and Keytruda combination study earlier this year, SITC provides the ideal platform to provide an update on progress with this study."

[divmad] 14/10/2020 07:07

The only trouble with that interview was that, when asked about the company's finances, DP said they were "very good. Strong". That answer devalued a lot else of what he said.

[showmethemoneyhoney01] 14/10/2020 07:04

I would have thought local MP's are the first to lobby. Maybe someone here who understands the procedure well in the Covid trial process could post something that others can copy and paste and send to their MP? Could 4D not get Merck to assist with getting trials in the US underway?

[beaujolly] 14/10/2020 06:57

As ever, I believe it's important to see the key statements in presentations in black and white and I've actually asked the Company if all transcripts could be published, as they did for the first webinar in September.
With reference to Blautix:
"we are really excited by what we see"
"the clinicians we have spoken to think its really positive"
"a one stop primary care treatment"
"works in both IBS C and D"
"improvement in bowel habits is really strong and very significant"
but as I said last night, the stand out for me was:
"518 works as a monotherapy as well"
I'm awaiting a reply from quite a long mail to the Company, so I don't want to contact them again but I wonder if someone could make contact to ask if investors can help on the CV19 enrolment front. I'd like it bounced off the Company first because I don't want any action to be counter productive.
But I'd like 4D's view on us contacting the press and MP's over a situation that frankly I find scandalous. The fact that DP went public with it, is in itself very telling. Yet again the politicians are looking after their friends in big business and people are dying.
Any volunteers ?

[the stigologist] 13/10/2020 23:28

According to Hem.Onc.Trader on twitter look out for #SITC2020 speakers/papers 'reveal' on October 14 and November 2

[daveweld2] 13/10/2020 22:39

Agree with the recent posts, the wolves are circling to mop up, In my mind a few changes...1. Vaccine collaboration2. 0518/keytruda3. 0518 mono4. Asthma5. Blautix6. Neuro degeneration 7. CovidNot a bad repertoire 1. & 2. We're the highlights of DPs previous IG tv interview prior to him being reminded of vaccine NDA imho

[devonlad] 13/10/2020 22:32

Pp_7 you're probably closer to the truth than you think. This is being worked make no mistake, very clever though.

[royalalbert] 13/10/2020 22:24

A TR1 of the positive nature, would put the cat amongst the pigeons.

[frrinvest] 13/10/2020 22:18

Best interview so far from DP. Very positive, I believe all along that share transfer is taking place to the big boys. I like it and happy to hold.

[royalalbert] 13/10/2020 22:14

If PI's wish to sell it's their prerogative. However II's and Merck are not Lemmings.

[pp_7] 13/10/2020 22:09

So we have, in the short term (2 to 3 months) the following to look forward to:I) Oncology updateII) CV19/Asthma updateIII) VaccinesIV) IBS Phase 3That's for starters...It's inconceivable, in my mind at least, that big pharma and major investors (particularly in the US) have not looked at SERES and the wider potential for LBT with serious intent. On paper 4D is at the forefront for this game and yet here we are share price dipping below £1 despite the massive strides made in last 6 months.Am convinced now that the fall last week was orchestrated to allow some large positions to be built up at the expense of PIs as the sheer volumes traded is seems too high for retail investors alone. Just surprised not to see any TR1s

[the stigologist] 13/10/2020 21:28

A reminder of how fast things can change...

This from March in the 20s (we're now 4x up 6 months later DESPITE a "Placing" and DESPITE a 'Phase II Clinical Trial 'FAIL')

I'm super confident we'll be at least 4x up within 6 months and would not rule out 10x+

Personally if I was looking for predictions on share prices I'd trust people who were calling this at the lows rather than jonny-come-latelies

----------------------------------------------------------------------------



----------------------------------------------------------------------------

[ambyth] 13/10/2020 21:22

I reckon > c.£15 within a year is about right too.

[thepaddedcell] 13/10/2020 21:20

Having watched todays youtube presentation again I'm more than happy to be invested in 4D. Plenty to look forward to by ways of news updates in several areas in the next couple of months.

[royalalbert] 13/10/2020 21:14

£15 a share, rather bullish Stig, although it is possible. As stated before I'm here for the Oncology.

[the stigologist] 13/10/2020 21:09

Just take advantage of the weak hand/brain sellers by buying.

Worked at 20s, 30s, 40s etc

I reckon even my 150p buys will work and be up 10x at least this time next year